U.S. Markets open in 3 hrs
  • S&P Futures

    -6.75 (-0.20%)
  • Dow Futures

    -52.00 (-0.18%)
  • Nasdaq Futures

    -23.00 (-0.20%)
  • Russell 2000 Futures

    +2.00 (+0.12%)
  • Crude Oil

    +0.26 (+0.65%)
  • Gold

    -10.50 (-0.54%)
  • Silver

    -0.33 (-1.29%)

    -0.0027 (-0.2250%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    +0.13 (+0.44%)

    -0.0032 (-0.2413%)

    +0.1120 (+0.1071%)

    +1,900.89 (+17.19%)
  • CMC Crypto 200

    +15.08 (+6.16%)
  • FTSE 100

    -25.93 (-0.45%)
  • Nikkei 225

    -92.73 (-0.39%)

Today’s Research Reports on Stocks to Watch: Aemetis, Inc. and Amyris Inc.

NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Shares of Aemetis and Amyris both saw gains on Tuesday with Aemetis scoring an impressive 65% close in the green. The company announced that it has completed the operation of a cellulosic ethanol integrated demonstration unit that produced record yields.

RDI Initiates Coverage on:

Aemetis, Inc.

Amyris, Inc.

Aemetis, Inc. shares closed up 65.09% on nearly 11 million shares traded yesterday. The stock exploded after the company announced yesterday that it has successfully built and operated an integrated demonstration unit for more than 120 days of continuous operations with 94% uptime. Trades were excited to learn that this meets the requirements for a federal USDA 9003 Biorefinery Assistance Program guaranteed loan. CEO Eric McAfee stated, "The completion of the successful operation of the demonstration unit is the final technology step in securing a USDA loan guarantee for the $158 million cellulosic ethanol plant Aemetis is building in Riverbank, California. We believe that the integration of these technologies, and the high yields generated by the unit, demonstrate that Aemetis can successfully produce high value cellulosic ethanol from the 1.6 million tons of waste orchard wood and other renewable feedstocks in the Central Valley. With plans to expand the Riverbank plant and construct additional plants, Aemetis plans to be a leader in supplying California's low carbon fuels mandates."

Access RDI's Aemetis, Inc. Research Report at:

Amyris, Inc. shares closed up 5.97% on Tuesday with around 378,000 shares traded. There was no remarkable news to explain the big boost in price. The integrated renewable products company is expected to report financial results for the fourth quarter and fiscal year ended December 31,2017, on March 15th after the close. The stock has seen impressive gains in the last several months, bouncing from an all-time low of $1.86. The company announced at the beginning of February that Aprinnova, its joint venture with NIKKOL GROUP, has launched pharmaceutical grade Neossance® Squalane USP. The new material meets the industry standards of the U.S. Pharmacopeia, and the National Formulary for drug actives and pharmaceutical excipients. Senior Vice President of Personal Care for the company, Caroline Hadfield, remarked, "We are very pleased to have met the USP and NF requirements, which showcases our adherence to a philosophy of manufacturing and distributing the highest performance, sustainable products through a best-in-class production process. We are delighted to provide a sustainable and naturally-sourced squalane to this important new market for Aprinnova while providing our customers and their end market customers with non-animal, cruelty-free high-performance ingredients for a growing variety of products."

Access RDI's Amyris, Inc. Research Report at:

Our Actionable Research on Aemetis, Inc. (NASDAQ: AMTX) and Amyris, Inc. (NASDAQ: AMRS) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.


For any questions, inquiries, or comments reach out to us directly at:


Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011



CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com